We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fibrotech is Granted US and Canadian Patents
News

Fibrotech is Granted US and Canadian Patents

Fibrotech is Granted US and Canadian Patents
News

Fibrotech is Granted US and Canadian Patents

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fibrotech is Granted US and Canadian Patents"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Fibrotech has announced that it has been granted patents in the USA and Canada relating to the Company’s proprietary novel anti-fibrotic compounds.

The US patent is entitled “Halogenated Analogues of Anti-Fibrotic Agents” and the Canadian patent is entitled “Therapeutic Compounds”. Both have been granted composition of matter claims.

Prof. Darren Kelly, CEO of Fibrotech commented: “We are poised to announce Phase I results for our lead product so the granting of these patents is timely and will help us greatly in ongoing partnering discussions.”

Fibrotech entered the clinic in 2013 with its lead product FT011 for diabetic nephropathy. Kidney failure in diabetes occurs as a result of kidney fibrosis (scarring). This fibrosis is in turn due to the long term damage from excessive sugar levels in the blood. The results from a Phase I trial of FT011 will shortly be released.

Professor Darren Kelly, CEO of Fibrotech will be attending BIOEurope Spring in Turin on 10th and 11th of March and will be happy to meet with interested journalists and other parties there.

Advertisement